Real-time, once-daily monitoring of symptoms and FEV1 in cystic fibrosis patients - A feasibility study using a novel device

Clinical Respiratory Journal

Volumn 4, Issue 2, 2010, Pages 74-82

  Sarfaraz, Sunny ^a   Sund, Zoe ^a   Jarad, Nabil ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Cystic fibrosis; Electronic daily monitoring; Pulmonary exacerbation

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DIAGNOSTIC VALUE; DISEASE EXACERBATION; EARLY DIAGNOSIS; ELECTRONICS; FEASIBILITY STUDY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROCESS MONITORING; REAL TIME ELECTRONIC MONITORING SYSTEM; SCORING SYSTEM; SPIROMETRY; SYMPTOMATOLOGY; VALIDITY; COMPLICATION; DEVICES; DISEASE COURSE; HOSPITAL INFORMATION SYSTEM; MEDICAL RECORD; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PNEUMONIA; TELEMEDICINE;

ADULT; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEASIBILITY STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MEDICAL RECORDS; PATIENT COMPLIANCE; PNEUMONIA; POINT-OF-CARE SYSTEMS; SPIROMETRY; TELEMEDICINE;

EID: 77949892542     PISSN: 17526981     EISSN: 1752699X     Source Type: Journal    
DOI: 10.1111/j.1752-699X.2009.00147.x     Document Type: Article

References (25)

1. Goss CH, Burns JL. Exacerbation of cystic fibrosis. 1: epidemiology and pathogenesis. Thorax. 2007 62 : 360 367.
2. Marshall BC. Pulmonary exacerbation in cystic fibrosis. It's time to be explicit. AJRCCM. 2004 169 : 781 782.
3. Ramsay BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med. 1996 335 : 179 188.
4. Liu TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5 years survivorship model of cystic fibrosis. Am J Epidemiol. 2001 153 : 345 352.
5. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent exacerbations on quality of life on patients with cystic fibrosis. Chest. 2002 121 : 64 72.
6. Jarad NA, Jeffcote T, Higgs S, Giles K. Factors influencing reduced FEV1 in adult patients with cystic fibrosis in a relatively affluent area. Chronic Respir J. 2005 2 : 133 137.
7. Ramsay BW, Boat TF. Outcome measures for clinical trials in cystic fibrosis. Summary of a cystic fibrosis consensus conference. J Pediatr. 1994 124 : 177 192.
8. Konstan MW, Byard PT, Hoppel CL, Davies PB. Effect of high-dose ibuprofen in patients with CF. N Engl J Med. 1995 332 : 848 854.
9. Ramsay BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Efficacy and safety of chronic intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999 340 : 23 30.
10. Fuchs HJ, Borowitz DS, Christiansin DH, Morris EM, Nash ML, Ramsay BW. Effect of aerolised recombinant human DNase on exacerbation of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994 331 : 637 642.
11. Dakin C, Henry RL, Field P, Morton J. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol. 2001 31 : 436 442.
12. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery B, Ramsay B. Defining pulmonary exacerbation in cystic fibrosis. J Paediatr. 2001 139 : 359 365.
13. Doring G, Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis - a European consensus. J Cyst Fibros. 2004 3 : 67.
14. Cystic Fibrosis Foundation. Microbiology and Infectious Disease in Cystic Fibrosis: V (section 1). Bethesda, MD, Cystic Fibrosis Foundation, 1994.
15. Wilkinson TM, Donaldson GC, Hurst JR, et al. Early therapy improves outcome of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004 169 : 1298 1303.
16. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 157 : 1418 1422.
17. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002 57 : 847 852.
18. British Thoracic Society and the Association of Respiratory Technicians and Physiologists. Guidelines for the measurement of respiratory function. Respir Med. 1994 88 : 165 194.
19. Finkelstein SM, Wielinski CL, Kujawa SJ, Loewenson R, Warwick WJ. The impact of home monitoring and daily diary recording on patient status in cystic fibrosis. Pediatr Pulmonol. 1992 12 (1 3 10.
20. Finkelstein SM, Budd JR, Warwick WJ, Kujawa SJ, Wielinski CL, Ewing LB. Feasibility and compliance studies of a home measurement monitoring program for cystic fibrosis. J Chronic Dis. 1986 39 (3 195 205.
21. Brown-Ewing LJ, Finkelstein SM, Budd JR, Kuajawa SJ, Wielinski CL, Warwick WJ, Nguyen S. Implementation of a home based programme for early detection of clinical deterioration in cystic fibrosis. Med Instrum. 1988 22 : 240 246.
22. Slagle JR, Finkelstein SM, Leung LA, Warwick WJ. Monitor: an expert system that validates and interprets time-dependent partial data based on a cystic fibrosis home monitoring programme. IEEE Trans Biomed Eng. 1989 36 : 552 558.
23. Sund ZM, Powell T, Greenwood R, Jarad NA. Remote daily real-time monitoring in patients with COPD - A feasibility study using a novel device. Respir Med. 2009 doi:10.1016/j.rmed.2009.03.017.
24. Rodriguez-Roison R. Towards a consensus definition for COPD exacerbation. Chest. 2000 117 : 398S 401S.
25. Cellie B, McNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004 23 : 932 946.